EXAS Exact Sciences
- 60.010
- -1.680-2.72%
Exact Sciences News
Buy Rating Affirmed for Exact Sciences Amid Promising Cancer Screening Innovations and Strategic Advantages
Jefferies Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $84
Jefferies Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $75
Exact Sciences Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Alignment Healthcare (ALHC), Exact Sciences (EXAS) and Fulcrum Therapeutics (FULC)
Scotiabank Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $70
A Quick Look at Today's Ratings for Exact Sciences(EXAS.US), With a Forecast Between $67 to $88
Exact Sciences Price Target Cut to $67.00/Share From $91.00 by Benchmark
UBS Cuts Exact Sciences' Price Target to $61 From $66, Maintains Neutral Rating
Exact Sciences Analyst Ratings
Stifel Maintains Buy on Exact Sciences, Lowers Price Target to $82
Buy Rating Affirmed for Exact Sciences on Strong Financials and Promising Growth Catalysts
A Quick Look at Today's Ratings for Exact Sciences(EXAS.US), With a Forecast Between $67 to $88
Exact Sciences (EXAS) Gets a Buy From Stifel Nicolaus
Benchmark Co. Remains a Buy on Exact Sciences (EXAS)
Analysts' Opinions Are Mixed on These Healthcare Stocks: GE Healthcare Technologies Inc (GEHC), United Therapeutics (UTHR) and Exact Sciences (EXAS)
Strong Q2 Performance and Growth Trajectory Justify Buy Rating for Exact Sciences
Exact Sciences (EXAS) Receives a Buy From Piper Sandler
Exact Sciences Analyst Ratings
Exact Sciences Analyst Ratings
Analysis
Price Target
No Data
